S1013: A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18(FACT-EGFRI 18) Questionnaire for EGFRI-Induced Skin Toxicities
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Cetuximab (Primary) ; Erlotinib (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer; Lung cancer
- Focus Adverse reactions
- 13 Dec 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
- 13 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2018.
- 16 Feb 2017 Status changed from recruiting to active, no longer recruiting.